menu
    • menu
    [{"orgOrder":0,"company":"Omnix Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"OMN6","moa":"Gram-negative bacterial membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Omnix Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omnix Medical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Omnix Medical \/ Undisclosed"},{"orgOrder":0,"company":"Omnix Medical","sponsor":"EIC Accelerator","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2021","type":"Funding","leadProduct":"OMN6","moa":"Gram-negative bacterial membrane","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Omnix Medical","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Omnix Medical \/ EIC Accelerator","highestDevelopmentStatusID":"5","companyTruncated":"Omnix Medical \/ EIC Accelerator"},{"orgOrder":0,"company":"Omnix Medical","sponsor":"Harel Insurance & Finance | EIC Fund | Entree Capital |Tal Ventures | Xenia Ventures |Oriella Limited | Prevail Partners | OurCrowd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2025","type":"Series C Financing","leadProduct":"OMN6","moa":"Gram-negative bacterial membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Omnix Medical","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Omnix Medical \/ Harel Insurance & Finance | EIC Fund | Entree Capital |Tal Ventures | Xenia Ventures |Oriella Limited | Prevail Partners | OurCrowd","highestDevelopmentStatusID":"8","companyTruncated":"Omnix Medical \/ Harel Insurance & Finance | EIC Fund | Entree Capital |Tal Ventures | Xenia Ventures |Oriella Limited | Prevail Partners | OurCrowd"}]

    Find Clinical Drug Pipeline Developments & Deals by Omnix Medical

    Menu

    Omnix Medical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Omnix Medical

                            Israel arrow
                            Tides Europe
                            Not Confirmed

                            Omnix Medical

                            Israel arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OMN6

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Harel Insurance & Finance | EIC Fund | Entree Capital |Tal Ventures | Xenia Ventures |Oriella Limited | Prevail Partners | OurCrowd

                            Deal Size : $25.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Omnix Medical Raises $25M in Series C Funding with Harel Insurance & EIC Fund

                            Details : The Series C financing for OMN6, an unconjugated peptide targeting Gram-negative bacterial membrane, will advance treatments for infections caused by Gram-negative bacteria.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            October 15, 2025

                            Lead Product(s) : OMN6

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Harel Insurance & Finance | EIC Fund | Entree Capital |Tal Ventures | Xenia Ventures |Oriella Limited | Prevail Partners | OurCrowd

                            Deal Size : $25.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Omnix Medical

                            Israel arrow
                            Tides Europe
                            Not Confirmed

                            Omnix Medical

                            Israel arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OMN6

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex

                            Details : OMN6 is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pneumonia, Ventilator-Associated.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            October 17, 2023

                            Lead Product(s) : OMN6

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Omnix Medical

                            Israel arrow
                            Tides Europe
                            Not Confirmed

                            Omnix Medical

                            Israel arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OMN6

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : EIC Accelerator

                            Deal Size : $13.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Omnix Medical Wins €10.8M in EIC Accelerator Funding

                            Details : Funding secures the advancement of Omnix Medical’s lead compound OMN6 through Phase I and II clinical trials. OMN6 is a novel antimicrobial peptide for treating life-threatening infections caused by Gram-negative bacteria.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            January 25, 2021

                            Lead Product(s) : OMN6

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : EIC Accelerator

                            Deal Size : $13.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth